SUBLOCADE Drug Patent Profile

Which patents cover Sublocade, and when can generic versions of Sublocade launch?

Sublocade is a drug marketed by Indivior and is included in one NDA. There are thirteen patents protecting this drug.

This drug has sixty patent family members in thirty-two countries.

The generic ingredient in SUBLOCADE is buprenorphine. There are twenty-nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the buprenorphine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sublocade

A generic version of SUBLOCADE was approved as buprenorphine by WATSON LABS TEVA on November 20^th, 2018.

Summary for SUBLOCADE

International Patents:	60
US Patents:	13
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SUBLOCADE

US Patents and Regulatory Information for SUBLOCADE

SUBLOCADE is protected by twenty-five US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Indivior	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes
Indivior	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes
Indivior	SUBLOCADE	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	209819-002	Nov 30, 2017		RX	Yes	Yes			Y

International Patents for SUBLOCADE

When does loss-of-exclusivity occur for SUBLOCADE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

New Zealand

Norway

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SUBLOCADE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011263478	Injectable flowable composition comprising buprenorphine
Brazil	112012031290	composição fluidificável injetável compreendendo buprenorfina
Canada	2801676	COMPOSITIONS (COMPOSITIONS)

SUBLOCADE (buprenorphine extended-release) investment scenario and patent-licensing fundamentals

Last updated: July 22, 2026

Executive summary: SUBLOCADE is a high-barrier, brand-only buprenorphine depot franchise with an FDA-defined exclusivity stack tied to multiple NDA-protecting events plus a patent estate that has shaped slow-to-enter generic competition. Near-term investor focus is on (1) how much patent runway remains for depot-specific compositions, methods of use, and manufacturing process claims, (2) whether any ANDA-based generic or authorized generics can launch without triggering repeat paragraph IV litigation, and (3) whether payer dynamics and opioid-use disorder (OUD) care models are shifting demand to alternative buprenorphine delivery systems (including sublingual and implant). For licensing and litigation posture, the question is not whether SUBLOCADE is protectable, but how enforceable the remaining depot-specific claims are against depot-ready dosing regimens and manufacturing workflows.

---

Is SUBLOCADE a good investment based on sales durability and category growth for opioid use disorder (OUD)?

What drives demand for SUBLOCADE

• OUD treatment model shift toward long-acting dosing: Depot formulations reduce adherence risk versus daily sublingual therapy, which can be a meaningful driver in high churn populations (housing instability, unstable access to clinics).
• Clinical and administrative fit: SUBLOCADE can be integrated into structured office-based opioid treatment (OBOT) workflows.
• Safety profile and retention: Buprenorphine’s ceiling effect on respiratory depression and the depot’s adherence support are central to retention.

Where revenue exposure is most sensitive

• Payer adoption and prior authorization friction: Depot therapy is more likely to face coverage controls than generics of sublingual buprenorphine.
• Site-of-care economics: Injection administration, REMS-like administration controls (if applicable under REMS requirements for buprenorphine products), and clinic capacity influence throughput.
• Switching risk to other buprenorphine long-acting products: Market share can erode if competing LA products are easier to procure or reimburse.

Investment read-through

• Best-case thesis: stable patient retention + broad payer contracting keeps brand revenue resilient while patent-protected exclusivity blocks ANDA-based competition.
• Bear-case thesis: payer hardening and substitution to other LA buprenorphine formats cap growth and compress price, increasing probability of faster erosion as protection weakens or if a settlement enables an earlier generic/authorized launch.

---

What patents protect SUBLOCADE (buprenorphine extended-release) and how strong is the remaining estate?

Core patent estate categories that matter to generics and biosimilar-like entry

For SUBLOCADE-like depot products, the enforceable claims typically cluster into:

• Depot composition claims: polymer matrix, drug-to-polymer ratio ranges, and solidification/implantation properties.
• Manufacturing process claims: solvent removal, mixing/processing windows, particle/crystallinity control, and depot sterilization/aseptic handling steps.
• Method-of-use claims: dosing regimens (initial titration vs maintenance), injection-site workflows, and patient population claims.
• Formulation variants: particle size, viscosity targets, and release-rate-limiting excipients that preserve controlled-release kinetics.

How investors should map patent coverage to entry routes

• If a generic pursues an ANDA: the company must satisfy sameness in composition and release profile, and it will be judged against Orange Book-listed patents covering composition, method of use, and potentially process.
• If a challenger pursues a 505(b)(2): the company may try to leverage public information and a bridging strategy; that can shift risk to formulation and method-of-use claims that survive around-the-edges design-arounds.
• If a challenger targets “non-infringing” releases: patent risk concentrates on claims capturing structural equivalence or functional release kinetics rather than only nominal ingredients.

Strength indicators that typically correlate with prolonged exclusivity

• Multiple family continuations with overlapping coverage
• Claims that address both composition and manufacturing
• Orange Book listing breadth across more than one dosage strength
• Prior litigation history that shows willingness to enforce depot-specific claims

---

When does SUBLOCADE lose exclusivity and what are the key FDA exclusivity timelines?

Exclusivity vs patent term

• Patent term: governs legal exclusivity after statutory expiration until the last relevant claim expires or is cleared by litigation/settlement.
• Regulatory exclusivity (statutory exclusivity, if applicable): blocks FDA approval even when patents expire, depending on exclusivity type and timing.

Investor timeline structure

For an investment model, investors should separate:

1. Regulatory exclusivity end (if any listed)
2. Last composition/process/method-of-use patent expiry
3. Potential Paragraph IV filing windows (typically telegraphed by first ANDA submissions)

Commercial consequence

• The first feasible competitive launch date is typically the earliest date when both regulatory and patent barriers are cleared.
• If litigation settlements occur, the “real” launch can shift from the theoretical expiry date to a court- or agreement-driven entry date.

---

What is the Orange Book status of SUBLOCADE and how many patents are listed?

How to interpret Orange Book listings for investment

Orange Book provides the practical view of what blocks generic entry:

• Number of listed patents per active ingredient
• Patent types (composition, method of use, and manufacturing)
• Expiration dates by patent
• Whether any patents are marked for “use” or multiple dosage forms

Decision logic for investors

• More listed patents + staggered expiries = longer effective exclusivity wall and higher likelihood of litigation.
• Fewer listed patents with clustered expiries = higher probability of a near-term ANDA launch once a key barrier clears.

---

Which companies are challenging SUBLOCADE with ANDAs or Paragraph IV certifications?

Why Paragraph IV matters economically

• A Paragraph IV ANDA filing signals a challenger’s belief they can:
  • design around remaining claims, or
  • invalidate claims, or
  • obtain a carve-out/section viii-to-court outcome that clears approval.
• It usually precedes settlement dynamics that set an entry date.

Investment implication

• If there are active Paragraph IV disputes, near-term valuation is sensitive to:
  • court scheduling,
  • claim construction outcomes,
  • settlement timing,
  • remaining patent survival.
• If no active challenges exist, the valuation rests more on patent expiry calendars and payer-driven share risks.

---

What patent litigation affects SUBLOCADE and how do settlements change launch risk?

Litigation mechanics investors model

• Infringement posture: whether the challenger targets the depot formulation or the manufacturing steps.
• Validity posture: whether key claims are attacked on obviousness, lack of enablement, or prior art anticipation.
• Injunction likelihood: determines whether an approved generic can be blocked until design changes or appellate outcomes.

Settlement outcomes investors should track

Settlements typically:

• establish an agreed entry date,
• allow marketing of a generic after a “trigger” date,
• specify carve-outs around certain patents while preserving others.

Commercial consequence

• Even when a theoretical patent expiry exists, settlement often drives the earliest practicable launch.

---

How does SUBLOCADE compare with other buprenorphine long-acting products for patent and market risk?

Competitive landscape dimensions

• Delivery system substitutability: patients and payers decide between depot, implant, and sublingual regimens based on clinic workflow and adherence outcomes.
• Coverage and rebates: brand placement can be supported by formulary tier status.
• Administration constraints: depot products require controlled administration protocols.

Investment read-through vs substitutes

• If alternatives expand coverage and reduce administration friction, SUBLOCADE’s effective revenue ceiling drops, even if patent barriers remain intact.

---

What formulations are protected by SUBLOCADE patents and what are the design-around barriers?

Depot formulation features that usually get claimed

• polymer matrices used for controlled release
• drug loading specifications
• viscosity and injectability properties
• release kinetics profiles that match in vivo behavior
• sterile processing and packaging conditions linked to stability

Design-around risk

A generic can attempt:

• different polymer sources
• modified particle size distributions
• altered manufacturing parameters to achieve non-infringing compositions
• different dosing regimen schedules

Patent enforceability rises when claims are drafted around:

• compositional ranges,
• structural equivalents,
• functional release thresholds,
• and/or manufacturing steps that are hard to change without affecting depot behavior.

---

What method-of-use patents exist for SUBLOCADE dosing regimens and patient populations?

Why dosing claims create entry friction

Method-of-use claims can be violated even if a generic is “composition close” but has different titration logic or administration steps. If dosing regimens remain within the claimed ranges:

• non-infringing labeling is harder,
• FDA labeling carve-outs become more contested in litigation.

Investor modeling angle

• The more method-of-use coverage remains active, the more likely that a challenger must negotiate a settlement to obtain workable labeling and launch timing.

---

What generic entry risks exist for SUBLOCADE after patent expiry?

Entry pathways that can still fail economically

• Scientific barrier: matching release kinetics to prove “sameness” under FDA standards.
• Regulatory barrier: labeling and REMS-like administration controls, if any, complicate launch.
• Legal barrier: lingering process and method-of-use claims can keep FDA approval tethered to a “carve-out” pathway.

Timing risk that affects valuation

• Even after a key patent expires, launch can be delayed by:
  • manufacturing scale-up,
  • validation,
  • stability and bridging studies,
  • and final negotiated labeling language.

---

What is SUBLOCADE’s FDA regulatory status and what does it mean for market access?

Pathway and labeling risk

• SUBLOCADE’s regulatory status impacts:
  • whether entry competitors need full NDA vs 505(b)(2),
  • whether labeling restrictions constrain substitution.

Reimbursement is the practical limiter

Even if regulatory entry is feasible, payer contracting determines uptake and price realization.

---

Investment scenario: base case, bull case, bear case

Base case (patent wall holds; gradual share pressure)

• SUBLOCADE retains dominant depot positioning.
• Generic entry does not arrive until the last listed barrier clears or a settlement sets a later entry date.
• Growth is constrained by market access dynamics, but revenue remains supported by retention.

Bull case (strong durability + delayed generic launch)

• Patent enforcement blocks or delays challengers.
• Payer contracts support depot penetration.
• Alternatives do not displace meaningful share.

Bear case (earlier-than-modeled entry or settlement carve-out)

• One or more Orange Book-listed patents fall, are invalidated, or are cleared by settlement.
• A generic/authorized product enters with workable labeling and distribution.
• Price erosion accelerates as payers move toward lower-cost substitutes.

---

Key patent-and-regulatory diligence checkpoints for investors

What to track each quarter

• changes in Orange Book listings tied to SUBLOCADE
• court docket milestones in any ongoing Paragraph IV matters
• any settlement announcements altering entry timelines
• payer formulary shifts that show substitution to other buprenorphine delivery systems

What changes the equity story fastest

• A new ANDA filing with a credible Paragraph IV theory against core depot claims
• a consent judgment or settlement that sets a launch date
• a patent expiry that unblocks a broader set of generic labeling options

---

Key Takeaways

• SUBLOCADE’s investment profile hinges on the effective exclusivity wall created by Orange Book-listed patents plus any regulatory exclusivity milestones.
• The highest-value diligence is mapping each Orange Book-listed patent family to actual generic design-around routes: depot composition, depot manufacturing, and method-of-use dosing regimens.
• The fastest valuation inflection comes from active Paragraph IV litigation milestones or settlements that set practical launch dates.
• Commercial risk is driven by payer access and substitutability to other long-acting buprenorphine delivery options, even when patent protection remains intact.

---

FAQs

1. How do Orange Book-listed method-of-use patents affect generic labeling for SUBLOCADE?
2. What manufacturing-process claim types most commonly block ANDA entry for depot buprenorphine products?
3. When do patent settlements typically set the earliest launch date relative to statutory patent expiration for SUBLOCADE-style products?
4. How does payer prior authorization change the economic advantage of long-acting buprenorphine depots versus sublingual therapy?
5. What clinical endpoints (retention/adherence) most influence whether depot substitution accelerates during brand-to-generic transitions?

---

References (APA)

1. FDA Orange Book. U.S. FDA. (Orange Book listing accessed via FDA Orange Book database).
2. U.S. Food and Drug Administration. Approved drug products and related information. (FDA databases and labels for SUBLOCADE).